Inebilizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders.

Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 27, 2026

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Journal: Rheumatology and therapy

Published: March 31, 2026

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Journal: Neurological research and practice

Published: March 24, 2026

Management of IgG4-Related Disease.

Management of IgG4-Related Disease.

Journal: Current rheumatology reports

Published: March 18, 2026

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.

Journal: Journal of neuroimmunology

Published: March 15, 2026

A Systematic Review of Erdheim-Chester Disease and IgG4-Related Disease: Building a Diagnostic Framework for the Rheumatologist.

A Systematic Review of Erdheim-Chester Disease and IgG4-Related Disease: Building a Diagnostic Framework for the Rheumatologist.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: February 23, 2026

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials.

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials.

Journal: Expert opinion on biological therapy

Published: February 20, 2026

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

Journal: Clinical pharmacology and therapeutics

Published: January 31, 2026

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Journal: Handbook of clinical neurology

Published: January 12, 2026

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 06, 2026

Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.

Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.

Journal: Annals of clinical and translational neurology

Published: December 26, 2025

Showing 1-12 of 180

Last Updated: 06/30/2026